EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo

Stanley C Xie iD, Chia-Wei Tai, Craig J Morton, Liting Ma, Shih-Chung Huang, Sergio Wittlin, Yawei Du, Yongbo Hu, Con Dogovski, Mina Salimimarand, Robert Griffin, Dylan England und 28 weitere

PLOS Pathogens · 09.12.2024 · 20 (12) · e1012429

DOI: 10.1371/journal.ppat.1012429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 09.12.2024. Verfasst von Stanley C Xie und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, A…. Hauptthemen laut MEDLINE: Plasmodium falciparum, Malaria, Falciparum, Antimalarials, Tyrosine-tRNA Ligase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Medical Research Council, Global Health Innovative Technology Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Plasmodium falciparum cytoplasmic tyrosine tRNA synthetase ( Pf TyrRS) is an attractive drug target that is susceptible to reaction-hijacking by AMP-mimicking nucleoside sulfamates. We previously identified an exemplar pyrazolopyrimidine ribose sulfamate, ML901, as a potent reaction hijacking inhibitor of Pf TyrRS. Here we examined the stage specificity of action of ML901, showing very good activity against the schizont stage, but lower trophozoite stage activity. We explored a series of ML901 analogues and identified ML471, which exhibits improved potency against trophozoites and enhanced selectivity against a human cell line. Additionally, it has no inhibitory activity against human ubiquitin-activating enzyme (UAE) in vitro . ML471 exhibits low nanomolar activity against asexual blood stage P . falciparum and potent activity against liver stage parasites, gametocytes and transmissible gametes. It is fast-acting and exhibits a long in vivo half-life. ML471 is well-tolerated and shows single dose oral efficacy in the SCID mouse model of P . falciparum malaria. We confirm that ML471 is a reaction hijacking inhibitor that is converted into a tight binding Tyr-ML471 conjugate by the Pf TyrRS enzyme. A crystal structure of the Pf TyrRS/ Tyr-ML471 complex offers insights into improved potency, while molecular docking into UAE provides a rationale for improved selectivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumMalaria, FalciparumAntimalarialsTyrosine-tRNA LigaseMice, SCIDAnimalsMiceHumansAdministration, OralProtozoan ProteinsEnzyme InhibitorsPyrimidines

Substanzen

AntimalarialsTyrosine-tRNA LigaseProtozoan ProteinsEnzyme InhibitorsPyrimidines

Autor:innen und Institutionen

  • Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia.
  • Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Biomedical Manufacturing Program, CSIRO, Clayton South, Victoria, Australia.
  • Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States of America.
  • Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
  • University of Basel, Basel, Switzerland.

ORCID-Profile: Stanley C Xie, Leann Tilley

Förderung

  • Gates Foundation
  • Medical Research Council
  • Global Health Innovative Technology Fund
  • National Health and Medical Research Council
  • Australian Research Council
  • Medicines for Malaria Venture
  • The Foundation for Research Support of the State of São Paulo
  • National Research Foundation

Zitieren

APA

Xie, S. C., Tai, C. W., Morton, C. J., Ma, L., Huang, S. C., Wittlin, S., Du, Y., Hu, Y., Dogovski, C., Salimimarand, M., Griffin, R., England, D., de la Cruz, E., Deni, I., Yeo, T., Burkhard, A. Y., Striepen, J., Schindler, K. A., Crespo, B., …, & Tilley, L. (2024). A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo. PLOS Pathogens, 20(12), e1012429. https://doi.org/10.1371/journal.ppat.1012429

Vancouver

Xie SC, Tai CW, Morton CJ, Ma L, Huang SC, Wittlin S, et al. A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo. PLOS Pathogens. 2024;20(12):e1012429. doi:10.1371/journal.ppat.1012429

BibTeX
@article{Xie2024,
  author = {Xie, Stanley C and Tai, Chia-Wei and Morton, Craig J and Ma, Liting and Huang, Shih-Chung and Wittlin, Sergio and Du, Yawei and Hu, Yongbo and Dogovski, Con and Salimimarand, Mina and Griffin, Robert and England, Dylan and de la Cruz, Elisa and Deni, Ioanna and Yeo, Tomas and Burkhard, Anna Y and Striepen, Josefine and Schindler, Kyra A and Crespo, Benigno and Gamo, Francisco J and Khandokar, Yogesh and Hutton, Craig A and Rabie, Tayla and Birkholtz, Lyn-Marié and Famodimu, Mufuliat T and Delves, Michael J and Bolsher, Judith and Koolen, Karin M J and van der Laak, Rianne and Aguiar, Anna C C and Pereira, Dhelio B and Guido, Rafael V C and Creek, Darren J and Fidock, David A and Dick, Lawrence R and Brand, Stephen L and Gould, Alexandra E and Langston, Steven and Griffin, Michael D W and Tilley, Leann},
  title = {A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo},
  journal = {PLOS Pathogens},
  year = {2024},
  volume = {20},
  number = {12},
  pages = {e1012429},
  doi = {10.1371/journal.ppat.1012429}
}
Kostenlos starten →